Vor Biopharma (NASDAQ:VOR) Stock Falls 8.2% – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR)’s share price fell 8.2% on Wednesday. The stock traded as low as $20.41 and last traded at $20.2050. 428,626 shares traded hands during trading, a decline of 59% from the average session volume of 1,056,572 shares. The stock had previously closed at $22.00.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 14th. Finally, Wedbush upped their target price on Vor Biopharma from $18.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.71.

Vor Biopharma Stock Down 4.8%

The firm’s fifty day simple moving average is $22.13 and its two-hundred day simple moving average is $17.83.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.69) by ($0.11). Equities research analysts predict that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Engineers Gate Manager LP lifted its stake in Vor Biopharma by 37.5% during the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock worth $680,000 after purchasing an additional 10,071 shares in the last quarter. Braidwell LP lifted its position in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after purchasing an additional 106,330 shares in the last quarter. Wellington Management Group LLP purchased a new position in shares of Vor Biopharma in the second quarter valued at approximately $499,000. Bank of New York Mellon Corp acquired a new position in shares of Vor Biopharma in the second quarter valued at approximately $1,799,000. Finally, Bank of America Corp DE increased its stake in Vor Biopharma by 28,408.1% during the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock worth $2,014,000 after buying an additional 112,496 shares during the period. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.